Pfizer Shares Rise Amid Sangamo Partnership Termination
Pfizer shares slightly increased despite ending its collaboration with Sangamo. Explore what this means for investors and the future of biotech cooperation.
Topic
Sangamo
A collection of 8 issues
Sangamo Seeks New Partners for Hemophilia Treatment
Sangamo is actively seeking new partnerships to advance its innovative hemophilia treatment. Discover the company's strategic moves in the biopharma landscape.
Sangamo Reclaims Rights to Hemophilia Gene Therapy from Pfizer
Sangamo Therapeutics regains rights to giroctocogene fitelparvovec after Pfizer's successful Phase 3 trials, marking a pivotal shift in hemophilia gene therapy.
Sangamo's Stock Drops Amid Partnership Dissolution
Sangamo's stock declines as investors react to partnership dissolutions. Discover the impact on market sentiment and future outlook.
Pfizer Ends Partnership with Sangamo on Hemophilia A Therapy
Pfizer terminates its partnership with Sangamo, citing limited interest in advancing another hemophilia A gene therapy. Explore the implications for biotech innovation.
Pfizer's Withdrawal Hits Sangamo with Negative Sentiment
Explore the impact of Pfizer's withdrawal on Sangamo, leading to negative market sentiment. Key insights into biotech market dynamics.
Sangamo's Market Value Nears $500 Million
Discover how Sangamo's market value was just below $500 million before recent developments. Stay updated on biotech market trends and company valuations.
Sangamo Shares Plunge After Pfizer Ends Gene Therapy Deal
Sangamo stock drops sharply as Pfizer terminates collaboration on hemophilia A gene therapy. Explore the impact on Sangamo's market position and future plans.